(9Ci)-4-[[(1,1-二甲基乙氧基)羰基]氨基]四氢-2H-硫代吡喃-4-羧酸,1,1-二氧化物 | 369402-94-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (9Ci)-4-[[(1,1-二甲基乙氧基)羰基]氨基]四氢-2H-硫代吡喃-4-羧酸,1,1-二氧化物
• 英文名称: 4-N-Boc-amino-4-carboxy-1,1-dioxo-tetrahydrothiopyran
• 英文别名: 4-BOC-Amino-4-Carboxy-1,1-Dioxo-Tetrahydrothiopyran；4-[(2-methylpropan-2-yl)oxycarbonylamino]-1,1-dioxothiane-4-carboxylic acid
• CAS: 369402-94-8
• 化学式: C₁₁H₁₉NO₆S
• mdl: MFCD02683147
• 分子量: 293.341
• InChiKey: NECDODYCDAMCKY-UHFFFAOYSA-N

物化性质

• 沸点：
  540.8±50.0 °C(Predicted)
• 密度：
  1.34±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.818
• 拓扑面积：
  118
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (9Ci)-4-[[(1,1-二甲基乙氧基)羰基]氨基]四氢-2H-硫代吡喃-4-羧酸,1,1-二氧化物 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 以97%的产率得到4-氨基-1,1-二氧代-四氢-2H-硫代吡喃-4-羧酸
  参考文献：
  名称：

  Inhibition of glutamate racemase by substrate–product analogues

  摘要：

  D-Glutamate is an essential biosynthetic building block of the peptidoglycans that encapsulate the bacterial cell wall. Glutamate racemase catalyzes the reversible formation of D-glutamate from L-glutamate and, hence, the enzyme is a potential therapeutic target. We show that the novel cyclic substrate-product analogue (R,S)-1-hydroxy-1-oxo-4-amino-4-carboxyphosphorinane is a modest, partial noncompetitive inhibitor of glutamate racemase from Fusobacterium nucleatum (FnGR), a pathogen responsible, in part, for periodontal disease and colorectal cancer (K-i = 3.1 +/- 0.6 mM, cf. K-m = 1.41 +/- 0.06 mM). The cyclic substrate- product analogue (R, S)-4-amino-4-carboxy-1,1-dioxotetrahydro-thiopyran was a weak inhibitor, giving only similar to 30% inhibition at a concentration of 40 mM. The related cyclic substrate-product analogue 1,1-dioxo-tetrahydrothiopyran-4-one was a cooperative mixed-type inhibitor of FnGR (K-i = 18.4 +/- 1.2 mM), while linear analogues were only weak inhibitors of the enzyme. For glutamate racemase, mimicking the structure of both enantiomeric substrates (substrate-product analogues) serves as a useful design strategy for developing inhibitors. The new cyclic compounds developed in the present study may serve as potential lead compounds for further development. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.12.114

文献信息

• [EN] INDAZOLE AND PYRAZOLOPYRIDINE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS<br/>[FR] COMPOSÉS D'INDAZOLE ET DE PYRAZOLOPYRIDINE COMME ANTAGONISTES DU RÉCEPTEUR CCR1
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2011049917A1

  公开（公告）日：2011-04-28

  Diclosed are CCRl receptor antagonists of the formula (I), wherein X is nitrogen or, C-R2; Ar1 is carbocycle, heteroaryl or heterocyclyl each optionally substituted by one to three Ra; Ar2 is carbocycle, heteroaryl or heterocyclyl, each optionally substituted by one to three Rb; Cyclic G is carbocycle, or heterocyclyl each optionally substituted by one to two R8; R1 is hydrogen, C1-6 alkyl or C 1-6 alkoxyC1-6 alkyl. Also disclosed are compositions, methods of making and using compounds of the formula (I).

  已披露的CCRl受体拮抗剂的结构式（I），其中X为氮或C-R2；Ar1为碳环、杂环芳基或杂环烷基，每个都可以选择性地被一个到三个Ra取代；Ar2为碳环、杂环芳基或杂环烷基，每个都可以选择性地被一个到三个Rb取代；环G为碳环或杂环烷基，每个都可以选择性地被一个到两个R8取代；R1为氢、C1-6烷基或C1-6烷氧基C1-6烷基。还披露了结构式（I）化合物的组合物、制备方法和使用方法。
• Glycogen Phosphorylase Inhibitor Compounds and Pharmaceutical Compositions Thereof
  申请人：Evans Karen

  公开号：US20070249670A1

  公开（公告）日：2007-10-25

  The invention relates to glycogen phosphorylase inhibitor compounds, pharmaceutical compositions of these compounds, methods of treatment using the pharmaceutical compositions to treat diabetes, conditions associated with diabetes, and/or tissue ischemia, including myocardial ischemia, and processes for making the compounds.

  本发明涉及糖原磷酸化酶抑制剂化合物、这些化合物的药物组合物、使用这些药物组合物治疗糖尿病、与糖尿病相关的疾病和/或组织缺血，包括心肌缺血的方法，以及制备这些化合物的过程。
• Indazole and Pyrazolopyridine Compounds As CCR1 Receptor Antagonists
  申请人：Cook Brian Nicholas

  公开号：US20120270870A1

  公开（公告）日：2012-10-25

  Diclosed are CCR1 receptor antagonists of the formula (I) wherein Ar 1 , Ar 2 , R 1 , X and G are disclosed herein. Also disclosed are compositions, methods of making and using compounds of the formula (I).

  本发明公开了式(I)的CCR1受体拮抗剂，其中Ar1、Ar2、R1、X和G在此公开。还公开了式(I)化合物的组合物、制备方法和使用方法。
• MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO
  申请人：ARENA PHARMACEUTICALS, INC.

  公开号：US20140309192A1

  公开（公告）日：2014-10-16

  The present invention relates to compounds of Formula (I) and pharmaceutically acceptable salts, solvates, and hydrates thereof: that are useful in methods of treatment and alleviation of diseases and disorders of the heart, brain, kidney, immune, and reproductive system resulting from ischemia, or reperfusion subsequent to ischemia, and any downstream complication(s) related thereto. The present invention further relates to methods of treatment and alleviation of diseases and disorders of the vasculature resulting from vasoconstriction or hypertension and any downstream complication(s) resulting from elevated blood pressure and/or reduced tissue perfusion.

  本发明涉及公式（I）的化合物及其药学上可接受的盐、溶剂合物和水合物，这些化合物对于治疗和缓解由缺血引起的心脏、脑、肾脏、免疫和生殖系统的疾病和障碍以及缺血后再灌注及其相关的任何下游并发症具有用处。本发明还涉及治疗和缓解由血管收缩或高血压引起的血管病变及由升高的血压和/或组织灌注减少引起的任何下游并发症的方法。
• US9056858B2
  申请人：——

  公开号：US9056858B2

  公开（公告）日：2015-06-16